Sorin and Cyberonics have announced the appointment of Vivid Sehgal as chief financial officer of LivaNova, effective with the closing of the proposed merger of Sorin and Cyberonics. He will report directly to Andre-Michel Ballester, who will be the chief executive officer of LivaNova, and will be based in the company’s London headquarters.
Sehgal brings more than 25 years of financial, operational and compliance leadership, most recently with Allergan where he served as senior vice president, treasury, risk and investor relations, playing a lead role in the company’s capital deployment and risk strategies, culminating in the US$66bn sale of Allergan to Actavis.
Previously, Sehgal served as vice president and regional controller of Allergan’s Europe, Middle East and Africa business, where he was responsible for finance, accounting, information technology, market research, data quality and sales operations covering more than 60 countries. He played a key role in the formulation and execution of the group’s strategy for international acquisitions and expansion into key emerging markets.
Prior to Allergan, Sehgal worked in various roles with GlaxoSmithKline and SmithKline Beecham for nine years, with his last position being group controller for the International Pharmaceutical Division, with sales of more than US$13bn.
“Vivid brings a wide variety of experience to LivaNova, including the development of shared services, strategic planning, Sarbanes-Oxley implementation and merger integration,” commented Andre-Michel Ballester, designated chief executive officer of LivaNova and chief executive officer of Sorin. “We are delighted to welcome Vivid as a key member of our senior management team.”
Greg Browne, interim chief financial officer of LivaNova, will continue to support LivaNova in a transitional capacity until, as previously announced, his retirement in mid-year of 2016.